Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02631421 · ClinicalTrials.gov registry record
Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH
A clinical trial, sponsored by Vanderbilt University.
- Completed
- Registry status
- 15
- Enrollment target
NCT02631421 is a clinical trial that has completed, run by Vanderbilt University. The registered enrollment target is 15 participants.
The verdict
NCT02631421 has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
Right ventricular (RV) failure is the predominant cause of death in pulmonary arterial hypertension (PAH). No RV-specific therapies are available, in part because the underlying mechanisms of RV dysfunction are poorly understood. Given the heart's preference for fatty acids (FA) as an energy source, a deeper understanding of FA metabolism may shed light on RV adaptation to elevated afterload in PAH. The purpose of this study is to test the hypothesis that defects in fatty acid metabolism are common in PAH and contribute to RV failure. The investigators will measure peripheral and transcardiac lipid and glucose metabolites in PAH patients in comparison with patients with pulmonary venous hypertension and no evidence of pulmonary hypertension. The investigators will also correlate metabolites with concurrent measurement of right ventricular function.
Interventions
- OTHER Cardiac MRI
- PROCEDURE Blood Sampling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02631421
The ClinicalTrials.gov registry entry for NCT02631421 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cardiac MRI is the first listed.
NCT02631421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02631421 about?
NCT02631421 is a clinical study titled "Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH". Right ventricular (RV) failure is the predominant cause of death in pulmonary arterial hypertension (PAH). No RV-specific therapies are available, in part because the underlying mechanisms of RV dysfunction are poorly understood. Given the heart's preference for fatty acids (FA) as an energy source,...
What is the current status of trial NCT02631421?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2015-01. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02631421?
The interventions under investigation include: Cardiac MRI (OTHER), Blood Sampling (PROCEDURE).
Who is sponsoring clinical trial NCT02631421?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.